
MBX Stock Forecast & Price Target
MBX Analyst Ratings
Bulls say
MBX Biosciences is a promising clinical stage biopharmaceutical company with a strong focus on developing innovative, precision peptide therapies for endocrine and metabolic disorders. The company's proprietary PEP platform allows for optimized pharmaceutical properties and extended drug action and exposure, leading to less frequent dosing. Early Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist for obesity, showed promising results with potent weight loss and good GI tolerability, supporting its potential for once-monthly dosing. Upcoming catalysts for the company include the nomination of an amycretin prodrug candidate and the initiation of a Phase 3 trial for canvuparatide in hypoparathyroidism, adding to its diversified pipeline and growth potential. With a differentiated profile and strong potential, we maintain a positive outlook on MBX Biosciences Inc.
Bears say
MBX Biosciences is a clinical stage biopharmaceutical company with a promising pipeline of product candidates focused on endocrine and metabolic disorders. However, the recent weight loss data from its lead candidate, MBX 4291, showed a modest average weight reduction of 7% after just eight weeks, which may raise concerns about the effectiveness and market potential of its PEP platform. In addition, the company's lack of approved products and ongoing financial losses pose potential risks to its valuation and future commercial success, especially in a highly competitive obesity market.
This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
MBX Analyst Forecast & Price Prediction
Start investing in MBX
Order type
Buy in
Order amount
Est. shares
0 shares